Oncology Pipeline

For more than 50 years, Lilly has been dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them. Lilly is determined to build on this heritage and continue making life better for all those affected by cancer around the world. In 2019 Lilly created Loxo Oncology at Lilly, with the goal of rapidly delivering impactful new medicines for people with cancer. Our approach centers on creating new medicines that work in early clinical development and will matter to patients.

target icon View trials by
therapeutic target
phase icon View trials
by phase
cancer type icon View trials by
cancer type

Phase 3

CLL/SLL
BTK Inhibitor Enrolling
Pirtobrutinib (LOXO-305)
CLL/SLL
BTK Inhibitor Enrolling
Pirtobrutinib (LOXO-305)
CLL/SLL
BTK Inhibitor Enrolling
Pirtobrutinib (LOXO-305)
MCL
BTK Inhibitor Enrolling
Pirtobrutinib (LOXO-305)
Breast Cancer
Abemaciclib
Prostate Cancer
Abemaciclib
Prostate Cancer
Abemaciclib
Medullary Thyroid Cancer
RET Inhibitor Enrolling
Selpercatinib
NSCLC
RET Inhibitor Enrolling
Selpercatinib
NSCLC
RET Inhibitor Enrolling
Selpercatinib
Breast Cancer
Imlunestrant

Phase 2

CLL/SLL or NHL
BTK Inhibitor Enrolling
Pirtobrutinib (LOXO-305)
Breast Cancer
Abemaciclib
Prostate Cancer
Abemaciclib
NSCLC, Medullary Thyroid Cancer, Papillary Thyroid Carcinoma, or Other Advanced Solid Tumors
RET Inhibitor Enrolling
Selpercatinib
Pediatric Cancer
RET Inhibitor Enrolling
Selpercatinib
Pediatric Cancer
Ramucirumab

Phase 1

Advanced Hematologic Malignancies
BCL-2 Inhibitor Enrolling
LOXO-338
Breast Cancer
Abemaciclib
Pediatric Cancer
Abemaciclib
Advanced Hematologic Malignancies
LY3410738
Advanced Solid Tumors
LY3410738
Colorectal Cancer, NSCLC, or Other Advanced Solid Tumors
LY3537982
Lung Cancer, Medullary Thyroid Cancer, Other Advanced Solid Tumors, or Thyroid Cancer
LOXO-260
Breast Cancer or Endometrial Cancer
Imlunestrant
Breast Cancer
Imlunestrant

The safety and efficacy of the agents under investigation have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available for the uses being investigated.